Nuvalent, Inc.
DelistedCIK 1861560fmd_0KMXZ7K64VXTSWE9JGEZDJ15E7Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Mar 31, 2026, 25 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 15 | 36 | 64 | 113 | 218 | 307 |
| Total operating expenses | 17 | 46 | 86 | 149 | 280 | 414 |
| Compensation and benefits | – | – | 30 | 29 | 44 | 73 |
| Operating income | (17) | (46) | (86) | (149) | (280) | (414) |
| Interest and investment income | – | 0 | 4 | 23 | 38 | 45 |
| Other non-operating income (expense) | 2 | (1) | 4 | 23 | 20 | (10) |
| Income before taxes | – | – | (82) | (126) | (260) | (425) |
| Income tax expense | – | – | 0 | 0 | 1 | 1 |
| Net income from continuing operations | – | – | (82) | (126) | (261) | (425) |
| Net income | (15) | (46) | (82) | (126) | (261) | (425) |